In a first aspect, the present invention relates to a method for the purification of virus compositions as well as biological macromolecular compounds in a sample comprising mixing the sample with osmolytes, like non-ionic organic polymers and contacting the mixed sample with a hydrophilic membrane, optionally washing the membrane, and eluting the virus preparations or biological macromolecular components from the membrane with an eluting solution containing reduced amounts or no osmolytes, like non-ionic organic polymer. Moreover, virus compositions and biological macromolecular components obtainable with the method according to the present invention are provided as well as the use of the method according to the present invention for purification of virus compositions including whole virus particles and virus-like particles or biological macromolecular components.

The present invention relates to a nanoperforator having a lipid-bilayer nanodisc and a membrane-structured protein surrounding the nanodisc and to a pharmaceutical composition having the nanoperforator as an active ingredient for preventing or treating viral infectious diseases. The use of the lipid-bilayer nanoperforator provided in the present invention can lead to the safe prevention or treatment of a disease caused by viral infection regardless of whether the virus is a variant or not, and thus the present invention can be widely used for the safe and effective treatment of viral infectious diseases.

The present invention provides a vector engineered virus designed to favor and infect cancers and their surrounding cells. This technique mitigates cancer's ability to evade the body's immune system by calling attention to the cells that are cancerous beginning with their earliest stage of development by infecting those cells with a vector engineered virus specifically designed to target tumors in formation. This invention teaches a system and method for identifying, tagging, targeting, and destroying cancer cells while preserving healthy tissue. Developing cancers have two primary traits/biomarkers in common; one being a higher than normal heat signature from elevated metabolic activity; with the second being an acidic or lower than normal pH factor resulting from the hypoxic micro environment resulting from the depletion of available oxygen. Simply stated, all or most cancers cancers have a heat signature greater than that of normal healthy cells and a pH factor lower than seen around normal healthy cells.

In certain embodiments, the present invention provides isolated replication defective non-integrating segmented viruses comprising a genome where at least one of the viral segments comprises a heterologous nucleotide sequence comprising a nucleotide segment that encodes an effector protein. Also provided are methods of using these viruses.

The present invention provides a modified influenza A virus (IAV) comprising, consisting of, or consisting essentially of at least one artificial gene segment comprising a duplicated packaging signal, the result of which is a modified IAV that is replication competent and avirulent, and when co-infected with a wild type virus leads to segment exchange and compromises the spread of both viruses as well as methods of making and using same and methods of using the IAVs in the treatment and prevention of influenza-related diseases.

RNA virus vectors comprising a gene encoding the DNA-dependent activator of interferon-regulatory factors (DAI) protein, and optionally further comprising a gene encoding the receptor-interacting serine; threonine-protein kinase 3 (RIPK3) may be used therapeutically to induce cell death, as well as an inflammatory immune response, against tumors and virally-infected cells.

The present invention teaches a system and method for identifying, targeting and destroying cancer cells without harming healthy tissue. This invention uses a vector engineered virus to selectively seek out cells that are both hotter than normal with a pH factor that is lower than normal thereby identifying cells that are cancerous regardless of location. Cancer succeeds for two reasons: i) rapid growth and ii) failure of the body's immune system to recognize the aberrant cells. This novel approach of using a dual vectored virus creates a dominant preference for locating and attaching to cancer cells, eliminating the need for chemotherapy, radiation therapy, and most major surgeries.

The invention relates to defective interfering viruses and defective interfering virus RNAs that are effective as antiviral agents. The invention also relates to methods for identifying defective interfering virus RNAs that can be used as effective antiviral agents.

RNA virus vectors comprising a gene encoding the DNA-dependent activator of interferon-regulatory factors (DAI) protein, and optionally further comprising a gene encoding the receptor-interacting serine/threonine-protein kinase 3 (RIPK3) may be used therapeutically to induce cell death, as well as an inflammatory immune response, against tumors and virally-infected cells.

The disclosure relates to defective interfering viruses and defective interfering virus RNAs that are effective as antiviral agents. The disclosure also relates to methods for identifying defective interfering virus RNAs that can be used as effective antiviral agents.